Across the recent three months, 10 analysts have shared their insights on Regeneron Pharmaceuticals REGN, expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 7 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 1 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1036.8, with a high estimate of $1184.00 and a low estimate of $850.00. This current average has increased by 5.22% from the previous average price target of $985.33.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Raises | Outperform | $1184.00 | $1096.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Neutral | $925.00 | $850.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1110.00 | $1076.00 |
| Evan David Seigerman | BMO Capital | Raises | Outperform | $1082.00 | $1055.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1076.00 | - |
| Carter Gould | Barclays | Raises | Overweight | $1020.00 | $935.00 |
| Brian Abrahams | RBC Capital | Announces | Outperform | $1076.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $850.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1045.00 | - |
| Tyler Van Buren | TD Cowen | Raises | Outperform | $1000.00 | $900.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regeneron Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Regeneron Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Regeneron Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
Discovering Regeneron Pharmaceuticals: A Closer Look
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Unraveling the Financial Story of Regeneron Pharmaceuticals
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Regeneron Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.58% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 33.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.56%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 3.55%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
